Humana Inc. a leading health and well-being company, today introduced a new value-based care agreement with Thyme Care to provide comprehensive cancer care support for eligible Humana Medicare Advantage members. Value-based care is a holistic, patient-centered model designed to improve patient health outcomes and quality of life while helping to make healthcare more affordable and accessible. Cancer is the second-leading cause of death in the United States, with devastating physical

NLS Pharmaceutics Ltd. and Kadimastem Ltd. a clinical-stage company specializing in "off-the-shelf" allogeneic cell therapy products for neurodegenerative diseases and diabetes, in collaboration with iTolerance Inc. ("iTolerance"), a U.S. based regenerative medicine company, announced today the result from the  Type B pre-IND meeting held by Kadimastem and iTolerance with a committee of the U.S Food and Drug Administration ("FDA") on February 24, 2025, regar

HBM Alpha Therapeutics Inc., an innovative biotechnology company incubated by Harbour BioMed, announced a strategic collaboration and license agreement with a business partner to advance novel therapies targeting corticotropin-releasing hormone (CRH) for various disorders. Under the agreement, the partner gains exclusive global rights, excluding Greater China (mainland China, Taiwan, Hong Kong, and Macau), to develop and commercialize HAT001 (designated as HBM9013 by Harbour BioMed)

Sobi® and Apellis Pharmaceuticals today announced the European Medicines Agency (EMA) has validated an indication extension application for Aspaveli® (pegcetacoplan) for the treatment of C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), which are rare, chronic kidney diseases with no approved treatments. "C3G and IC-MPGN are severe and life-threatening kidney conditions, often leading to kidney failure and requiring a

CollPlant Biotechnologies, or "CollPlant", a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced the expansion of its distribution channels for its Vergenix™ STR product, in Europe and Asia. VergenixSTR is based on the Company's rhCollagen technology and is intended for the treatment of tendinopathy by promoting healing and repai

Cyrano Therapeutics, Inc., a clinical-stage regenerative medicine company pioneering the development of treatments for smell loss, announced today that it entered into an option agreement with KYORIN Pharmaceutical Co., Ltd. for CYR-064, a novel treatment for post-viral loss of smell (hyposmia). Under this agreement, KYORIN obtains an option for the license of the right to develop and commercialize CYR-064 in Japan and will pay an option fee to Cyrano. Upon exercising the option and

Nexalin Technology, Inc. the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, announces that it has received Institutional Review Board (IRB) approval from the University of California, San Diego (UCSD) for clinical testing of its HALO™ Clarity (HALO) headset in human subjects. This study is being conducted independently by UCSD. Nexalin is providing the HALO devices for research purposes but is not sponsoring, directing, or controlling the study or its outc

CJ Bioscience announced today that it will present preclinical data on its novel drug candidate CJRB-201 at the European Crohn's and Colitis Organization (ECCO) 2025, set to take place in Berlin, Germany. ECCO is a leading international conference in the field of inflammatory bowel disease (IBD), attracting gastroenterologists, researchers, and major pharmaceutical companies from around the world. CJRB-201 is a microbiome-based drug candidate identified through CJ Bioscience'

Sotera Health Company, a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the fourth-quarter and full-year ended December 31, 2024 before the market opens on Thursday, February 27, 2025. Following the release, management will hold a conference call at 9:00 a.m. Eastern Time to discuss the Company’s operating highlights and financ

URAC, the country's most complete health care accreditor, is taking a groundbreaking step in ensuring the responsible and effective use of artificial intelligence (AI) in health care. Today, URAC announced the intent to develop a new Health Care AI Accreditation, designed to provide organizations with guidance on the safe and ethical implementation of AI in health care settings, while supporting patient safety and understanding. The accreditation will serve as more than simply principles